866-997-4948(US-Canada Toll Free)

Schizophrenia Partnering 2007-2013

Published By :

Current Partnering

Published Date : Jul 2013

Category :

Diseases & Conditions

No. of Pages : 100 Pages

The Schizophrenia Partnering 2007-2013 provides understanding and access to the schizophrenia partnering deals and agreements entered into by the worlds leading healthcare companies .

The report provides an analysis of schizophrenia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 80 links to online copies of actual schizophrenia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of schizophrenia partnering trends.

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in schizophrenia partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading schizophrenia deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of schizophrenia partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of schizophrenia technologies and products.

Report scope

Schizophrenia Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to schizophrenia trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in schizophrenia dealmaking in the biopharma industry since 2007 
  • Access to summary headline, upfront, milestone and royalty data 
  • The leading schizophrenia deals by value since 2007 

In Schizophrenia Partnering 2007-2013, the available deals are listed by:

  • Headline value 
  • Upfront payment value 
  • Royalty rate value 
  • Company A-Z 
  • Industry sector 
  • Stage of development at signing 
  • Deal component type 
  • Technology type 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Schizophrenia Partnering 2007-2013 provides the reader with the following key benefits:

  • In-depth understanding of schizophrenia deal trends since 2007 
  • Access to summary headline, upfront, milestone and royalty data 
  • Comprehensive access to over 80 actual schizophrenia deals entered into by the worlds biopharma companies since 2007 
  • Insight into key deal terms included in contracts, where disclosed 
  • Understand the key deal terms companies have agreed in deals 
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in schizophrenia partnering

2.1. Introduction 
2.2. Schizophrenia partnering over the years
2.3. Bigpharma schizophrenia dealmaking activity
2.4. Schizophrenia partnering by deal type
2.5. Schizophrenia partnering industry sector
2.6. Schizophrenia partnering by stage of development
2.7. Schizophrenia partnering by technology type
2.8. Disclosed financial deal terms for schizophrenia partnering
2.8.1 Schizophrenia headline values
2.8.2 Schizophrenia upfront payments
2.8.3 Schizophrenia milestone payments
2.8.4 Schizophrenia royalty rates

Chapter 3 Leading schizophrenia disease deals
3.1. Introduction
3.2. Top schizophrenia deals by value
3.3. Top schizophrenia deals involving bigpharma

Chapter 4 Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Collaborative R&D
Contract service
Equity purchase
Joint venture
Spin out
4.4. By industry sector
Drug delivery
Medical device
Generic pharma
Research tools
Specialty pharma
4.5. By stage of development
Phase I
Phase II
Phase III
4.6. By technology type
Animal models
Biological compounds
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Discovery tools
DNA probes
Drug delivery
Enabling technology
Gene therapy
Industrial chemicals
In vitro models
Monoclonal antibodies
Personalised medicine
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Small molecules
Stem cells

Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking


Appendix 1 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports

List of Chart

Figure 1: Schizophrenia partnering since 2007 
Figure 2: Bigpharma top 50 schizophrenia deals 2007 to 2011 
Figure 3: Bigpharma schizophrenia deal frequency 2007 to 2011 
Figure 4: Schizophrenia partnering by deal type since 2007 
Figure 5: Schizophrenia partnering by industry sector since 2007 
Figure 6: Schizophrenia partnering by stage of development since 2007 
Figure 7: Schizophrenia partnering by technology type since 2007 
Figure 8: Schizophrenia deals with a headline value 
Figure 9: Schizophrenia deals with upfront payment values 
Figure 10: Schizophrenia deals with milestone payments 
Figure 11: Schizophrenia deals with royalty rates, % 
Figure 12: Top schizophrenia deals by value since 2007 
Figure 13: Top schizophrenia deals signed by bigpharma value since 2007 
Figure 14: Online partnering resources 
Figure 15: Forthcoming partnering events 
Figure 16: Deal type definitions 

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *